Sainte-Anne Hospital Center

Small Pharma to Present at Cowen’s 43rd Annual Health Care Conference

Retrieved on: 
Wednesday, March 1, 2023
MD, Harvard Medical School, Psychedelic drug, Conference, Chief scientific officer, Sainte-Anne Hospital Center, Psychiatry, Pharmaceutical industry

LONDON, March 01, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, is pleased to announce that George Tziras, Chief Executive Officer and Dr. Carol Routledge, Chief Medical and Scientific Officer, will participate in Cowen’s 43rd Annual Health Care Conference, taking place on March 6 - 8, 2023 at the Boston Marriott Copley Place.

Key Points: 
  • LONDON, March 01, 2023 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-duration psychedelic-assisted therapies for mental health conditions, is pleased to announce that George Tziras, Chief Executive Officer and Dr. Carol Routledge, Chief Medical and Scientific Officer, will participate in Cowen’s 43rd Annual Health Care Conference, taking place on March 6 - 8, 2023 at the Boston Marriott Copley Place.
  • Small Pharma will also host a cocktail reception with guest speaker Jerry Rosenbaum, MD, Stanley Cobb Professor of Psychiatry at Harvard Medical School, and Director of the Massachusetts General Hospital Center for Neuroscience of Psychedelics.
  • Details of the Company’s presentation and cocktail reception are as follows:
    To schedule a one-on-one meeting with Small Pharma’s management team, please contact [email protected] .

Crinetics Pharmaceuticals Appoints Dana Pizzuti, M.D. as Chief Development Officer

Retrieved on: 
Monday, October 3, 2022
Securities Exchange Act of 1934, Degenerative disease, Nasdaq, Wilms' tumor, Gilead Sciences, Time, Biology, SEC, Acromegaly, Pharmacovigilance, Form 10-K, Congenital hyperinsulinism, Research, Clinical trial, Drug Quality and Security Act, Drug discovery, Sainte-Anne Hospital Center, FDA, COVID-19, Infection, SST2, Employment, Program, SAN, Patient, Congenital adrenal hyperplasia, Carcinoid syndrome, Yale University, Annual report, Intellectual property, Securities Act of 1933, Bachelor of Science, Marketing, Therapy, GLOBE, ACTH, Pharmaceutical industry, Medicine

(Nasdaq: CRNX) today announced the appointment of Dana Pizzuti, M.D., as chief development officer.

Key Points: 
  • (Nasdaq: CRNX) today announced the appointment of Dana Pizzuti, M.D., as chief development officer.
  • Dr. Pizzuti added, Crinetics has constructed an impressive multi-asset pipeline, and it is an honor to be joining a company with such a robust discovery engine.
  • Before joining Crinetics, Dr. Pizzuti served as senior vice president, development operations and chief medical officer at Ascendis Pharma, where she rebuilt the U.S. regulatory affairs unit into a streamlined global organization.
  • Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.

CTMA Expands Its Digital Clinical Trial Solution to a Second Therapeutic Area – Rheumatology

Retrieved on: 
Thursday, February 3, 2022
Technology, Research, Clinical Trials, Software, Other Health, Health, General Health, Data Management, Science, Ankylosing spondylitis, Rheumatoid arthritis, Patient, Inflammatory bowel disease, Conditional sentence, Ulcerative colitis, Sainte-Anne Hospital Center, HCP, UC, Exercise, Technology, Rheumatology, Population, CD, IBD, Cros, Pharmaceutical industry, Medical device, CTMA

CTMA, a clinical research service company that is working to change the way patients are detected for clinical trials, announced that it is expanding its CT-SCOUT technology offering into a second therapeutic area rheumatology.

Key Points: 
  • CTMA, a clinical research service company that is working to change the way patients are detected for clinical trials, announced that it is expanding its CT-SCOUT technology offering into a second therapeutic area rheumatology.
  • Pierre Pellier, Chief Executive Officer of CTMA, said: We are thrilled to expand our platform by adding a new therapeutic area.
  • Building on its successful experience in inflammatory bowel disease (IBD), CTMA plans to continue expanding its offering to include additional therapeutic areas in order to accelerate clinical research.
  • CTMA is a clinical research service company that is working to change the way patients are detected for clinical trials.

Cinnabon Signs Historic Deal with Innovative Union Company to Open 130 Units in the Kingdom of Saudi Arabia

Retrieved on: 
Tuesday, November 30, 2021
IUC, School, Industry, Coffee, Awareness, Sainte-Anne Hospital Center, Public sector banks in India, QSR, Entrepreneurship, Education, COVID-19, Twitter, Restaurant, Dream, Airport, Facebook, Kingdom, Retail, Management

ATLANTA, Nov. 30, 2021 /PRNewswire/ --Cinnabon, the iconic bakery and purveyor of craveable cinnamon rolls, announced a groundbreaking deal with the Innovative Union Company (IUC) to bring 130 new Cinnabon bakeries to the Kingdom of Saudi Arabia (KSA) within the next five years.

Key Points: 
  • ATLANTA, Nov. 30, 2021 /PRNewswire/ --Cinnabon, the iconic bakery and purveyor of craveable cinnamon rolls, announced a groundbreaking deal with the Innovative Union Company (IUC) to bring 130 new Cinnabon bakeries to the Kingdom of Saudi Arabia (KSA) within the next five years.
  • Once the additional units open, IUC will be the largest Cinnabon franchisee in the world with 250 bakeries.
  • Established in 2000, the Innovative Union Company (IUC) has rapidly evolved from operating a single franchise in 2002 to a leading food service company.
  • The company has a wide presence across the Kingdom of Saudi Arabia, which it soon will expand into other countries in the MENA region.